Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 or Post-Vaccination in Libyan Population: Comparison of Four Vaccines

Ebrahim, Fawzi; Tabal, Salah; Lamami, Yosra; Alhudiri, Inas M; Meshri, Salah Edin El; Dwigen, Samira Al; Arfa, R.; Alboeshi, Asma; Alemam, Hafsa A.; Abuhtna, Fauzia; Altrhouni, Rabeeah; Milad, Mohamed B.; Elgriw, Nada A.; Ruaua, Mahmoud A.; Abusrewil, Zakarya; Harroush, Warda; Jallul, Mwada; Ali, Fouziyah S.; Eltaib, Farag; Elzagheid, Adam

doi:10.3390/vaccines10122002

Cited by 9 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The total number of infected individuals in the NCDC registry was 341091 on 30 th September 2021. Our results thus confirm the findings of previous studies on the protective effect of full vaccination as single dose vaccine immunity tends to wane faster and may not mount a good immune response after infection except in previously infected individuals (4). We also found no difference in in mortality between unvaccinated and partially vaccinated.…”

Section: Discussionsupporting

confidence: 90%

“…COVID-19 vaccinations have been approved for emergency use worldwide (3). The humoral immune responses elicited by four vaccines used in Libya were previously evaluated in the general population (4). This study showed that Sputnik V and AstraZeneca vaccines developed a robust antibody response especially in previously infected individuals higher than Sinovac and Sinopharm.…”

Section: Introductionmentioning

confidence: 99%

“…Vaccination with either one dose of Pfizer BioNtech or AstraZeneca (Vaxzevria) was associated with a substantial reduction in symptomatic infection in adults older than 70 years and with additional protection against severe disease and hospitalization (5). Patients who had received one dose of AstraZeneca had an extra reduction of admission with severe disease (4). Furthermore, vaccination was associated with lower hospital mortality (6).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of vaccination and risk factors on COVID-19 mortality amid delta wave in Libya: a single centre cohort study

Alhudiri¹,

Abusrewil

Dakhil³

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background The Delta variant has led to a surge in COVID-19 cases in Libya, making it crucial to investigate the impact of vaccination on mortality rates among hospitalized patients and critically ill. Aims To study risk factors and COVID-19 mortality rates among unvaccinated and vaccinated adults during delta wave at a single COVID-19 care centre in Tripoli, Libya. Methods The study involved two independent cohorts (n=341). One cohort was collected retrospectively from May 2021-August 2021 and the second cohort was prospectively collected from August 2021-October 2021 and most of them were during the Delta wave. The two cohorts were merged and analysed as one group. Results Most patients were male (60.5%) and 53.3% were >60 years. The vast majority of admitted patients did not have previous COVID-19 infection (98.9%) and were unvaccinated (90.3%). Among vaccinated, 30 patients had one dose and only 3 had two doses. Among patients who received one dose, 58.1% (18/31) died and 41.9% (13/31) survived. Most patients (72.2%) had a pre-existing medical condition. Multivariable prediction model showed that age >60 years was significantly associated with death (odds ratio=2.328, CI 1.456-3.724, p-value=<0.0001). Conclusion Previous infection or full vaccination against COVID-19 significantly reduces hospitalization and death, as most admitted patients were unvaccinated and not previously infected. However, a single vaccine dose may not be adequate, especially for older individuals and those with underlying medical conditions. High-risk older patients with comorbidities should be fully vaccinated and offered up to date bivalent COVID-19 booster doses.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of vaccination and risk factors on COVID-19 mortality amid delta wave in Libya: a single centre cohort study

Alhudiri¹,

Abusrewil

Dakhil³

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous infection with COVID-19 has previously been shown to cause robust and high levels of anti-SARS-CoV-2 antibodies in vaccinated individuals compared with unvaccinated people, but these antibodies decline rapidly over time. [47][48][49] Vaccination-induced antibodies may not generate sufficient immune memory; therefore, repeated booster vaccinations at regular intervals appear necessary. Further studies are needed to understand the dynamics of immune response decline to vaccines and infections.…”

Section: Discussionmentioning

confidence: 99%

Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients

Assaid

Arich

Charoute

et al. 2023

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses serious global public health problems. Characterization of the immune response, particularly antibodies to SARS-CoV-2, is important for establishing vaccine strategies. The purpose of this study was to evaluate longitudinally the kinetics of anti-SARS-CoV-2 antibodies against spike protein (S1) for up to 3 months in a cohort of 169 COVID-19 patients. We enrolled COVID-19 patients at two regional hospitals in Casablanca, Morocco, between March and September 2021. Blood samples were collected and N-specific IgM and S-specific IgG levels were measured by a commercial Euroimmun ELISA. IgM antibodies were assessed 2–5 (D00), 9–12 (D07), 17–20 (D15), and 32–37 (D30) days after symptom onset; IgG antibodies were assessed at these time points plus 60 (D60) and 90 (D90) days after symptom onset. We found that at 3 months after symptom onset, 79% of patients had detectable SARS-CoV-2-specific IgG antibodies, whereas their IgM seropositivity was 19% by 1 month after symptom onset. The IgM level decreased to 0.34 (interquartile range [IQR] 0.19–0.92) at 1 month after symptom onset, whereas the IgG level peaked at D30 (3.10; IQR 1.83–5.64) and remained almost stable at D90 (2.95; IQR 1.52–5.19). IgG levels were significantly higher in patients older than 50 years than in those younger than 50 at all follow-up time points (P < 0.05). Statistical analysis showed no significant difference in median anti-S1 antibody levels among infected patients based on gender or comorbidities. This study provides information on the longevity of anti-SARS-CoV-2 IgM and IgG antibodies in COVID-19 patients.

show abstract

“…11 Similar published observations were also made by our team at the Libyan Biotechnology Research Center. 5 Individuals younger than 50 years exhibited higher antibody titers compared to those older than 50 years. A study by Wolszczak et al demonstrated a significant agerelated difference in antibody levels among individuals who had received one dose of the COVID-19 vaccine.…”

Section: Comparison Of Total Anti-sars-cov-2 Antibody Levels In Vacci...mentioning

confidence: 95%

Single ChAdOx1 nCoV‐19 dose elicits stronger immune response in previously infected individuals than in SARS‐CoV2 naive persons

Ebrahim,

Alboueishi,

Alhudiri

et al. 2024

Immunity Inflam & Disease

Self Cite

View full text Add to dashboard Cite

BackgroundCurrent vaccines against COVID‐19 effectively reduce morbidity and mortality and are vitally important for controlling the pandemic. Between December 2020 and February 2021, adenoviral vector vaccines such as ChAdOx1 (AstraZeneca‐Oxford) were put in use. Recent reports demonstrate robust serological responses to a single dose of messenger RNA vaccines in individuals previously infected with SARS‐CoV‐2. We aimed to study the association between previous COVID‐19 infection and antibody levels after a single dose of ChAdOx1 nCoV‐19.MethodsThis cross‐sectional study was conducted on 657 individuals who were either convalescent or SARS‐CoV‐2 naive and had received one dose of ChAdOx1 (AstraZeneca). A questionnaire was used to collect data on age, sex, and self‐reported history of COVID‐19 infection. We then compared the average levels of immunoglobulin G (IgG) between the previously infected and COVID‐19‐naive participants.ResultsWe compared the antibody responses of individuals with confirmed prior COVID‐19 infection with those of individuals without prior evidence of infection. The mean antibody levels in those who reported no history of COVID‐19 infection were substantially lower than in those who were previously infected, in both males and females. Sex‐related differences were observed when we compared antibody levels between men and women. In males, anti‐S IgG antibody levels were higher in those who had been previously infected (156.1 vs. 87.69 AU/mL, p = .009), compared with the same pattern was observed in females (113.5 vs. 90.69 AU/mL, p = .005).ConclusionsPrevious COVID‐19 infection is associated with higher levels of SARS‐CoV‐2 antibodies following ChAdOx1 (AstraZeneca) vaccination. Our finding supports the notion that a single dose of ChAdOx1 nCoV‐19 administered post‐SARS‐CoV‐2 infection serves as an effective immune booster. This provides a possible rationale for a single‐dose vaccine regimen for previously infected individuals.

show abstract

Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 or Post-Vaccination in Libyan Population: Comparison of Four Vaccines

Cited by 9 publications

References 25 publications

Impact of vaccination and risk factors on COVID-19 mortality amid delta wave in Libya: a single centre cohort study

Impact of vaccination and risk factors on COVID-19 mortality amid delta wave in Libya: a single centre cohort study

Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients

Single ChAdOx1 nCoV‐19 dose elicits stronger immune response in previously infected individuals than in SARS‐CoV2 naive persons

Contact Info

Product

Resources

About